Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 163 participants.

Also called NCT04927299

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 163 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04927299
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04927299. Randomized; double masking; primary purpose treatment. Start 2022-06-30 (actual); primary completion 2023-08-15 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Losartan/Chlorthalidone vs Losartan/Hydrochlorothiazide in Essential Arterial Hypertension
Condition
Essential Arterial Hypertension
Intervention (Drug)
Losartan/Chlorthalidone in fixed dose
Intervention (Drug)
Losartan + hydrochlorothiazide in fixed dose
Lead sponsor
Laboratorios Silanes S.A. de C.V. (class: industry)

Record details

Record id
cardio:ct-nct04927299
Content hash
00302eb90f56f45e4f7648407aba12e6bd194620f246d5aa1687e0cc3e19791e